ADIL Adial Pharmaceuticals, Inc.

-

Adial Pharmaceuticals, Inc. Reported Earnings

Friday, August 14, 2026 · 12:00 AM ET

Adial Pharmaceuticals, Inc. (ADIL) reported a loss of $11.25 per share on revenue of $0.00 million for the second quarter ended June 2026. .

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

Earnings Whisper Grade
Power Rating
Reported Earnings
($11.25)
Earnings Whisper®
Consensus Estimate
Earnings Surprise
Earnings Growth-6,150.0 %
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth